Simulations Plus (NASDAQ:SLP) Reaches New 12-Month Low – Should You Sell?

Simulations Plus, Inc. (NASDAQ:SLP)’s share price hit a new 52-week low during trading on Wednesday . The stock traded as low as $27.20 and last traded at $27.34, with a volume of 12064 shares. The stock had previously closed at $27.62.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SLP. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. Stephens began coverage on Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price for the company. StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. KeyCorp assumed coverage on Simulations Plus in a research note on Monday, July 29th. They set an “overweight” rating and a $47.00 target price on the stock. Finally, BTIG Research reduced their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Simulations Plus Price Performance

The company has a 50 day simple moving average of $30.86 and a 200-day simple moving average of $38.49. The stock has a market cap of $602.90 million, a P/E ratio of 59.70 and a beta of 0.71.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. The firm’s revenue for the quarter was up 19.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.18 earnings per share. As a group, research analysts expect that Simulations Plus, Inc. will post 1.12 earnings per share for the current year.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $27.66, for a total transaction of $553,200.00. Following the transaction, the director now owns 3,462,584 shares in the company, valued at $95,775,073.44. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 60,750 shares of company stock worth $1,905,655. Company insiders own 20.90% of the company’s stock.

Institutional Trading of Simulations Plus

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Janney Montgomery Scott LLC bought a new position in Simulations Plus during the 1st quarter valued at approximately $208,000. Vanguard Group Inc. raised its holdings in Simulations Plus by 1.1% in the first quarter. Vanguard Group Inc. now owns 1,135,105 shares of the technology company’s stock worth $46,710,000 after buying an additional 12,636 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Simulations Plus in the first quarter worth approximately $57,000. Price T Rowe Associates Inc. MD increased its position in shares of Simulations Plus by 5.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,048 shares of the technology company’s stock valued at $414,000 after acquiring an additional 562 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in Simulations Plus in the 1st quarter worth approximately $1,082,000. 78.08% of the stock is owned by hedge funds and other institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.